Fluzoparib
艾瑞颐(Fluzoparib)
A Chinese-developed PARP inhibitor pill (Hengrui).
At a glance
China price
Verified pricing is not currently available.
NRDL (national insurance)
In NRDL.
Regulatory status
NMPA approved (2020); NRDL (2021)
What this meansSupported by a credible secondary source but not yet independently confirmed against a primary source.
SourceNo independent source on file.
NotesApproval status from public regulatory reporting.
What it treats
BRCA-mutated ovarian cancer.
Sources & verification
No independent source is currently on file. We have not independently verified this information.
Reader discussion
Public comments about Fluzoparib. Discussion is not medical advice, and a comment is not an endorsement or a verified fact. Open the full forum.